Pearl River's Acorda Therapeutics ceases operations, 97 jobs affected

Operations at Acorda are slated to wind down completely by June 1

News 12 Staff

•

Apr 8, 2024, 4:36 PM

•

Updated 261 days ago

KIYC: Retailers crack down on return fraud amid expected $150 billion in holiday returns

3ds ago

0:21

FDA: More than 2 million cans of Jarritos Coconut Water recalled over seal concerns

5ds ago

0:51

Party City closing down all of its stores, company says

5ds ago

1:38

Friday's Mega Millions drawing offers estimated $1.15 billion jackpot

1h ago

1:26

Last-minute holiday shoppers visit The Westchester Mall for the perfect gift

2ds ago

1:11

Last-minute holiday shopping in full swing at Hudson Valley malls

2ds ago

2:03

KIYC: Retailers crack down on return fraud amid expected $150 billion in holiday returns

3ds ago

0:21

FDA: More than 2 million cans of Jarritos Coconut Water recalled over seal concerns

5ds ago

0:51

Party City closing down all of its stores, company says

5ds ago

Pearl River's Acorda Therapeutics, a developer of therapies for neurological disorders such as Parkinson's disease, has announced its closure.

This decision will directly impact 97 employees, according to statements released by the company.

The company, known for its commitment to advancing treatments for challenging conditions, has filed for Chapter 11 bankruptcy. The closure comes despite recent negotiations for acquisition by Merz Therapeutics, signaling a shift in the company's trajectory.

Operations at Acorda are slated to wind down completely by June 15.